CEFTRIAXONE SODIUM FOR INJECTION BP 10 G
CEFTRIAXONE (CEFTRIAXONE SODIUM) : 10 G · DIN 02325632 · STERIMAX INC
Health Canada status: MARKETED
What is CEFTRIAXONE SODIUM FOR INJECTION BP?
CEFTRIAXONE SODIUM FOR INJECTION BP 10 G contains CEFTRIAXONE (CEFTRIAXONE SODIUM) : 10 G. It is listed in the Health Canada Drug Product Database under DIN 02325632, held by STERIMAX INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 21-Mar-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CEFTRIAXONE SODIUM FOR INJECTION BP used for?
Treatment of lower respiratory tract, urinary tract, skin, bone/joint, and intra-abdominal infections; bacterial septicemia; meningitis; and uncomplicated gonorrhea. Also for surgical prophylaxis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02325632 |
|---|---|
| Brand name | CEFTRIAXONE SODIUM FOR INJECTION BP |
| Generic / active ingredient | CEFTRIAXONE (CEFTRIAXONE SODIUM) : 10 G |
| Manufacturer | STERIMAX INC |
| Strength | 10 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01DD04 CEFTRIAXONE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Mar-2011 |
How is it administered?
Adults: 1-2 g daily (max 4 g). Pediatrics (1 mo-12 yr): 50-75 mg/kg/day. Administered IV (bolus over 5 min or infusion over 10-30 min) or IM (deep intragluteal).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. Protect from light. (Note: Specific stability for reconstituted solutions varies by diluent).
How is it supplied?
Vials: 250 mg, 500 mg, 1 g, 2 g. Pharmacy Bulk Vial: 10 g. Available in cartons of 1 or 10 vials. Stoppers are latex-free.
Contraindications
Hypersensitivity to ceftriaxone, cephalosporins, or penicillins; hyperbilirubinemic/preterm neonates; neonates (≤ 28 days) requiring calcium-containing IV solutions.
Warnings and precautions
Severe Cutaneous Adverse Reactions (SCAR), Clostridium difficile-associated disease (CDAD), hemolytic anemia, and risk of ceftriaxone-calcium precipitates.
Is CEFTRIAXONE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01DD04 CEFTRIAXONE. 13 of 41 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CEFTRIAXONE FOR INJECTION | 1 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02289695 |
| CEFTRIAXONE FOR INJECTION | 100 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02409968 |
| CEFTRIAXONE FOR INJECTION | 2 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02289709 |
| CEFTRIAXONE INJECTION, USP | 1000 MG / 50 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02499711 |
| CEFTRIAXONE INJECTION, USP | 2000 MG / 50 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02499738 |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 1 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02292270 |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 1 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02325616 |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 10 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02292297 |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 2 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02292289 |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 2 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02325624 |
Who else supplies CEFTRIAXONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFTRIAXONE appears in 7521 registered pack listings across 9 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.